Downloadable Slidesets

Share

Program Content

Activities

  • <i>EP</i>: PARPi Questions in OC
    ExpressPoints
    Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 06, 2021

    Expires: July 05, 2022

  • PARPi in Ovarian Cancer
    Global Experience Using PARP Inhibitors in the Treatment of Ovarian Cancer
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 01, 2021

    Expires: June 30, 2022

  • Managing PARPi related AEs
    How Can We Proactively Manage PARP Inhibitor–Related Adverse Events to Improve Quality of Life?
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 01, 2021

    Expires: June 30, 2022

  • PARPi combinations in OC
    Should PARP Inhibitors be Used Alone or in Combinations for Ovarian Cancer? The Influence of Patient and Disease Factors
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 01, 2021

    Expires: June 30, 2022

  • PARPi in practice
    How Do You Approach the Use of PARP Inhibitors in Practice?
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 01, 2021

    Expires: June 30, 2022

Faculty

cover img faculity

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

cover img faculity

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

cover img faculity

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Provided by

ProCE Banner

Supporters

AstraZeneca